Published online Nov 26, 2023. doi: 10.12998/wjcc.v11.i33.7972
Peer-review started: September 13, 2023
First decision: September 28, 2023
Revised: October 11, 2023
Accepted: October 30, 2023
Article in press: October 30, 2023
Published online: November 26, 2023
Processing time: 72 Days and 0.8 Hours
Acute myelitis (AM) can cause sudden sensory, motor and autonomic nervous dysfunction in patients, which negatively affects their daily activities and quality of life. Therefore, it is necessary to optimize exploration from a therapeutic perspective to curb the progression of the disease.
It is necessary to optimize the therapeutic strategy to improve the clinical outcomes of AM patients.
In this research, the effect of ganglioside (GM) combined with methylprednisolone sodium succinate (MPSS) on the curative effect and neurological function of patients with AM was investigated.
Of the 108 AM patients selected, 52 cases were treated with gamma globulin plus MPSS (control group) and 56 cases were treated with GM plus MPSS (observation group). The two groups were then comparatively analyzed from the following perspectives: Efficacy, neurological function (sensory and motor function scores), occurrence of adverse events, recovery (time to sphincter function recovery, limb muscle strength recovery above grade 2, and ambulation), and inflammatory factors [interleukin-6 (IL-6); C-reactive protein (CRP); tumor necrosis factor-α (TNF-α)].
The treatment efficacy and sensory and motor function scores of the observation group were significantly higher than those of the control group, while the total incidence of adverse events such as rash, gastrointestinal discomfort, dyslipidemia and osteoporosis, as well as recovery indexes such as the time to sphincter function recovery, limb muscle strength recovery above grade 2, and ambulation was significantly lower. In addition, IL-6, CRP, and TNF-α levels reduced markedly in the observation group after treatment, significantly lower than the baseline and those of the control group.
GM combined with MPSS shows significant advantages in enhancing efficacy and nerve function in patients with AM, accelerating recovery, inhibiting serum inflammation, and improving safety.
Our findings may provide new insights and clinical references for the management and treatment of patients with AM.